{"disease":{"id":"solid-tumor-patients-receiving-high-emetic-risk-multi-day-chemotherapy","name":"solid tumor patients receiving high emetic risk multi day chemotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04536558","title":"Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":352,"lead_sponsor_name":"Sun Yat-sen University","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}